Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX027N in moderate-to-severe atopic dermatitis
CTR20262477Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX027N in atopic dermatitis (AD), sponsored by Quxin Biopharmaceutical. Started Sep 2026; status: active.
02
Drugs
QX027N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20262477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262477.